Quick-Med is working with health care giant

Published: Saturday, January 1, 2005 at 6:01 a.m.
Last Modified: Friday, December 31, 2004 at 10:34 p.m.
Gainesville-based Quick-Med Technologies Inc. will collaborate with a division of the Johnson & Johnson Co. to investigate applications of its NIMBUS antimicrobial technology to advanced wound care products.
Quick-Med's NIMBUS technology is a family of advanced polymers that are bio-engineered to have antimicrobial or other properties with broad applications.
The six-month collaboration agreement is with Johnson & Johnson Wound Management, a division of ETHICON Inc., a Somerville, N.J. company of Johnson & Johnson.
"This collaboration is another validation of the capabilities of our NIMBUS technology," Quick-Med President David S. Lerner said.
While Lerner said the confidentiality requirement of the agreement prevents him from releasing more details about the collaboration, he did say the research will be conducted in Gainesville, where his company has its headquarters and laboratory.
Quick-Med (OTC Bulletin Board: QMDT), which was founded in 1999, focuses on two primary technologies, NIMBUS, and MultiStat - a family of technologies and compounds called Matrix Metalloproteinase Inhibitors (MMPIs).
Research indicates that MMPIs play a key role in a number of skin conditions, and have a broad spectrum of uses including cosmetic, pharmaceutical, and military/civil defense.
ETHICON develops and markets products for surgery in the areas of wound care and wound management, sports medicine, women's health and cardiovascular medicine.
Doris Chandler can be reached at (352) 374-5094 or chandld@gvillesun.com

Reader comments posted to this article may be published in our print edition. All rights reserved. This copyrighted material may not be re-published without permission. Links are encouraged.

Comments are currently unavailable on this article

▲ Return to Top